FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP)

Advanced Search

Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

Advanced Search
Custom Query

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Clear All

Query Builder

Query box

Clear All

For additional assistance using the Custom Query please check out our Help Page

CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners. As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.

i

FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP)

May 28, 2010
By United States. Advisory Committee on Immunization Practices. ...
Source: MMWR. Morbidity and mortality weekly report. 2010; 59(20):626-9.
Series: Weekly Report: Morbidity and Mortality Weekly Report (MMWR)

Details Related Documents You May Also Like

Details:

Journal Article:

Morbidity and Mortality Weekly Report (MMWR)
Corporate Authors:

United States. Advisory Committee on Immunization Practices. ; Centers for Disease Control and Prevention (U.S.)

United States. Advisory Committee on Immunization Practices. ; Centers for Disease Control and Prevention (U.S.) Less -
Description:

On October 16, 2009, the Food and Drug Administration (FDA) licensed bivalent human papillomavirus vaccine (HPV2; Cervarix, GlaxoSmithKline) for use in females aged 10 through 25 years. Cervarix is the second human papillomavirus (HPV) vaccine licensed for use in females in the United States. Quadrivalent HPV vaccine (HPV4; Gardasil, Merck & Co, Inc.) was licensed in 2006 for use in females aged 9 through 26 years, and the Advisory Committee on Immunization Practices (ACIP) recommended routine HPV4 vaccination of females aged 11 or 12 years, and catch-up vaccination for females aged 13 through 26 years (1). This report provides updated recommendations for routine and catch-up vaccination of females with either HPV2 or HPV4.
Subjects:

[+]

Adolescent Adult Antibody Formation Child Female Human Papillomavirus 16 Human Papillomavirus 18 Humans Immunization Schedule Licensure Papillomavirus Infections Papillomavirus Vaccines Randomized Controlled Trials As Topic Uterine Cervical Neoplasms Young Adult
Source:

MMWR. Morbidity and mortality weekly report. 2010; 59(20):626-9.
Series:

Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
ISSN:

0149-2195 (print);1545-861X (digital);
Pubmed ID:

20508593
Document Type:

Journal Article
Name as Subject:

United States. Food and Drug Administration.
Place as Subject:

United States
Pages in Document:

4 pdf pages
Volume:

59
Issue:

20
Collection(s):

Advisory Committee on Immunization Practices (ACIP) Guidelines and Recommendations Morbidity and Mortality Weekly Report (MMWR)
Main Document Checksum:

[+]

urn:sha-512:3445807cf59a04fb508d187e47844dfdf1e2e489e3ee089d047f62f0f92c151214933de7c2652475661667d4d82ad0b01ad7c4b8b8e9bdce1600985984970ce8
Download URL:

https://stacks.cdc.gov/view/cdc/7333/cdc_7333_DS1.pdf
File Type:

[PDF-1.33 MB]